{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T08:11:03Z","timestamp":1791965463739,"version":"4.3.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Jiangxi Provincial Natural Science Foundation for Distinguished Young Scholars","award":["Grant No. 20232ACB216014"],"award-info":[{"award-number":["Grant No. 20232ACB216014"]}]},{"name":"the Natural Science Foundation of Jiangxi","award":["Grant No. 20242BAB26142"],"award-info":[{"award-number":["Grant No. 20242BAB26142"]}]},{"name":"oundation of Jiangxi Provincial Key Laboratory of Urinary System Diseases","award":["2024SSY06111"],"award-info":[{"award-number":["2024SSY06111"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of P.R. China","doi-asserted-by":"crossref","award":["Grant No. 82460497"],"award-info":[{"award-number":["Grant No. 82460497"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06476-0","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:04:24Z","timestamp":1780502664000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cytoreductive nephrectomy improves survival in metastatic papillary renal cell carcinoma: a population-based study with machine learning validation and landmark analysis"],"prefix":"10.1007","volume":"44","author":[{"given":"Ruize","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangxu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songhui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"issue":"10021","key":"6476_CR1","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/S0140-6736(15)00046-X","volume":"387","author":"U Capitanio","year":"2016","unstructured":"Capitanio U, Montorsi F (2016) Renal cancer. Lancet (London England) 387(10021):894\u2013906","journal-title":"Lancet (London England)"},{"issue":"1","key":"6476_CR2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","volume":"70","author":"PA Humphrey","year":"2016","unstructured":"Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE (2016) The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol 70(1):106\u2013119","journal-title":"Eur Urol"},{"issue":"23","key":"6476_CR3","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMoa003013","volume":"345","author":"RC Flanigan","year":"2001","unstructured":"Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC et al (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345(23):1655\u20131659","journal-title":"N Engl J Med"},{"issue":"9286","key":"6476_CR4","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","volume":"358","author":"GH Mickisch","year":"2001","unstructured":"Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet (London England) 358(9286):966\u2013970","journal-title":"Lancet (London England)"},{"issue":"5","key":"6476_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1803675","volume":"379","author":"A M\u00e9jean","year":"2018","unstructured":"M\u00e9jean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K et al (2018) Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med 379(5):417\u2013427","journal-title":"N Engl J Med"},{"issue":"27","key":"6476_CR6","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1200\/JCO.2016.66.7931","volume":"34","author":"N Hanna","year":"2016","unstructured":"Hanna N, Sun M, Meyer CP, Nguyen PL, Pal SK, Chang SL et al (2016) Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. J Clin oncology: official J Am Soc Clin Oncol 34(27):3267\u20133275","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"2","key":"6476_CR7","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/j.clgc.2016.07.016","volume":"15","author":"MR Matrana","year":"2017","unstructured":"Matrana MR, Baiomy A, Campbell M, Alamri S, Shetty A, Teegavarapu P et al (2017) Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib. Clin Genitourin Cancer 15(2):e205\u2013e8","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"6476_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.2007.13.3223","volume":"26","author":"TK Choueiri","year":"2008","unstructured":"Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S et al (2008) Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin oncology: official J Am Soc Clin Oncol 26(1):127\u2013131","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"10275","key":"6476_CR9","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","volume":"397","author":"SK Pal","year":"2021","unstructured":"Pal SK, Tangen C, Thompson IM Jr., Balzer-Haas N, George DJ, Heng DYC et al (2021) A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet (London England) 397(10275):695\u2013703","journal-title":"Lancet (London England)"},{"key":"6476_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","volume":"94","author":"TK Choueiri","year":"2018","unstructured":"Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O et al (2018) Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J cancer (Oxford England: 1990) 94:115\u2013125","journal-title":"Eur J cancer (Oxford England: 1990)"},{"issue":"1","key":"6476_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.eururo.2018.09.016","volume":"75","author":"B Bhindi","year":"2019","unstructured":"Bhindi B, Abel EJ, Albiges L, Bensalah K, Boorjian SA, Daneshmand S et al (2019) Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 75(1):111\u2013128","journal-title":"Eur Urol"},{"issue":"4","key":"6476_CR12","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.eururo.2014.05.034","volume":"66","author":"DY Heng","year":"2014","unstructured":"Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ et al (2014) Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 66(4):704\u2013710","journal-title":"Eur Urol"},{"issue":"3","key":"6476_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivar Behav Res 46(3):399\u2013424","journal-title":"Multivar Behav Res"},{"issue":"446","key":"6476_CR14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc 94(446):496\u2013509","journal-title":"J Am Stat Assoc"},{"key":"6476_CR15","doi-asserted-by":"crossref","unstructured":"Silagy AW, Flynn J, Mano R, Blum KA, Marcon J, DiNatale RG et al (2019) Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. Urologic oncology. ;37(11):811.e9-811.e16","DOI":"10.1016\/j.urolonc.2019.07.011"},{"issue":"2","key":"6476_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","volume":"5","author":"A Bex","year":"2019","unstructured":"Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU et al (2019) Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol 5(2):164\u2013170","journal-title":"JAMA Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06476-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06476-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06476-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:04:26Z","timestamp":1780502666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06476-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6476"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06476-0","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study utilized publicly available, de-identified data from the SEER database and was therefore exempt from institutional review board approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"407"}}